Zoetis Inc. (NYSE:ZTS) Shares Sold by Investment Management Corp of Ontario

Investment Management Corp of Ontario reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 30.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,091 shares of the company’s stock after selling 12,498 shares during the quarter. Investment Management Corp of Ontario’s holdings in Zoetis were worth $4,577,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of ZTS. JPMorgan Chase & Co. grew its position in shares of Zoetis by 10.6% in the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after purchasing an additional 279,092 shares during the period. Baker Tilly Wealth Management LLC increased its position in shares of Zoetis by 20.6% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 2,080 shares of the company’s stock worth $339,000 after acquiring an additional 356 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Zoetis by 64.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 409,703 shares of the company’s stock valued at $66,753,000 after purchasing an additional 160,826 shares during the period. Harbor Capital Advisors Inc. raised its holdings in shares of Zoetis by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 9,569 shares of the company’s stock valued at $1,559,000 after buying an additional 234 shares during the period. Finally, Czech National Bank boosted its stake in shares of Zoetis by 6.0% in the fourth quarter. Czech National Bank now owns 97,822 shares of the company’s stock valued at $15,938,000 after purchasing an additional 5,531 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,862 shares of company stock valued at $312,254. 0.18% of the stock is currently owned by insiders.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $159.96 on Friday. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The stock has a market capitalization of $71.37 billion, a P/E ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business has a 50-day moving average of $157.27 and a two-hundred day moving average of $166.06.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.20 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.38 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on ZTS. Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Morgan Stanley lowered their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. UBS Group cut their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday. Stifel Nicolaus decreased their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research report on Monday, April 14th. Finally, Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $212.13.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.